Article Sidebar

Submitted
Apr 15, 2021
Published
Apr 15, 2021
Download
PDF
Statistic
Read Counter : 53 Download : 32

Main Article Content

Abstract

High blood pressure is classified as either primary (essential) high blood pressure or secondary high blood pressure. The target of this study is to assess the efficiency of resveratrol in managing blood pressure in members diagnosed with prehypertension and stage 1 hypertension. The main objectives of this trial are to regulate the BP-lowering actions of resveratrol on systolic, diastolic, and mean arterial BP in members diagnosed with prehypertension and stage 1 hypertension. The outcomes from this study will help to decide the effectiveness of short-term resveratrol treatment in hypertensive patients and connect the gap with regards to the recent preclinical and clinical evidence. The primary results in this study will be BP. Systolic and diastolic BPs will be measured by using a mercury sphygmomanometer twice on patient in a sitting position after a 10-minute rest and with a 15-minute interval. The measurement will be done every week during the intervention period. The mean systolic and diastolic BP will be computed. Mean arterial pressure will be calculated as systolic blood BP plus two times the diastolic BP divided by three [(SBP + 2 × DBP) ÷ 3]. This study will also help in gathering further data with regard to recognizing a therapeutically effectual dose of resveratrol in reducing cardiovascular disease risk factors. Importantly, if a positive outcome is identified, it will provide us with an effectual therapeutic strategy to fight against hypertension and would pave the way for reaching enormous population well-being sake. Pharmacokinetics may have assisted to draw a relation between the plasma bioavailability and the actual physiological effect. In this trial, stage 1-hypertensive patients will be on quality therapy for hypertension as well; therefore, it may not be feasible to understand the standalone effictiveness of resveratrol in lowering BP in these patients.

Keywords

Sphygmomanometer Enormous Therapeutically Resveratrol

Article Details

How to Cite
K.Anitha, B. Anusha, M.Archana, B. Anjali, B. Aruna Kumari, & C. Anitha. (2021). A randomized double blinded placebo controlled trail on efficacy of resveratrol in controlling hypertension. International Journal of Research in Pharmacology & Pharmacotherapeutics, 6(2), 155-162. https://doi.org/10.61096/ijrpp.v6.iss2.2017.155-162
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1]. Eurosurveillance editorial team. Who launches the world health statistics? Euro Surveill. 2012, 17.
  2. [2]. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, et al. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension. 61, 2013, 1360–83. f.
  3. [3]. Appel LJ, Brands MW, Daniels SR, Karanja N, Elmer PJ, Sacks FM. Dietary approaches to prevent and treat hypertension: a scientific statement from the American Heart Association. Hypertension. 47, 2006, 296–308.
  4. [4]. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association professional education committee of the council for high blood pressure research. Hypertension. 51, 2008, 1403–19.
  5. [5]. Swain JF, McCarron PB, Hamilton EF, Sacks FM, Appel LJ. Characteristics of the diet patterns tested in the optimal macronutrient intake trial to prevent heart disease (omniheart): options for a heart-healthy diet. J Am Diet Assoc. 108, 2008, 257–65.
  6. [6]. Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. ClinNutr. 34(1), 2015, 27–34.
  7. [7]. Rodriguez-Leyva D, Weighell W, Edel AL, LaVallee R, Dibrov E, Pinneker R, et al. Potent antihypertensive action of dietary flaxseed in hypertensive patients. Hypertension. 62, 2013, 1081–9.
  8. [8]. Raj P, Louis XL, Thandapilly SJ, Movahed A, Zieroth S, Netticadan T. Potential of resveratrol in the treatment of heart failure. Life Sci. 95, 2014, 63–71.
  9. [9]. Thandapilly SJ, Louis XL, Behbahani J, Movahed A, Yu L, Fandrich R, et al. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens Res. 36, 2013, 866–72.
  10. [10]. Csiszar A, Labinskyy N, Olson S, Pinto JT, Gupte S, Wu JM, et al. Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats. Hypertension. 54, 2009, 668–75.
  11. [11]. Chun C, Yang W, Xueding C, Qi Z, Xiaoying H, Honglei X, et al. Resveratrol downregulates acute pulmonary thromboembolism-induced pulmonary artery hypertension via p38 mitogen-activated protein kinase and monocyte chemoattractant protein-1 signaling in rats. Life Sci. 90, 2012, 721–7.
  12. [12]. Mattison JA, Wang M, Bernier M, Zhang J, Park SS, Maudsley S, et al. Resveratrol prevents high fat/sucrose diet-induced central arterial wall inflammation and stiffening in nonhuman primates. Cell Metab. 20, 2014, 183–90.
  13. [13]. Movahed A, Nabipour I, Lieben Louis X, Thandapilly SJ, Yu L, Kalantarhormozi M, et al. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. eCAM. 2013, 2013, 851267.
  14. [14]. Bhatt JK, Thomas S, Nanjan MJ. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr Res. 32, 2012, 537–41. doi: 10.1016/j.nutres.2012.06.003.
  15. [15]. Raper NPB, Ingwersen L, Steinfeldt L, Jaswinder A. An overview of usda’s dietary intake data system. J Food Comp Anal. 17, 2004, 545. doi: 10.1016/j.jfca.2004.02.013.
  16. [16]. AshwoodCABaER . Tietz textbook of clinical chemistry. Philadelphia: W.B Saunders; 1999.
  17. [17]. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18, 1972, 499–502
  18. [18]. Kim Y, Park I, Kang M. Convergent validity of the international physical activity questionnaire (ipaq): meta-analysis. Public Health Nutr. 16, 2013, 440–52.